SCHEMBL4397295

SCHEMBL4397295

O=C(O)CC[C@H](NC(=O)c1cc(F)c(N(CCI)CCI)c(F)c1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
CA2 P00918 4/20 0.44
CA1 P00915 3/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
FOLH1 Q04609 6/20 0.44
TYMS P04818 4/20 0.42
DHFR P00374 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6508607 0.88 KDM4E (0.47) KDM4EHPGDCA2CA1CA12
SCHEMBL6510663 0.88 KDM4E (0.47) KDM4EHPGDCA2CA1CA12
SCHEMBL6509794 0.85 KDM4E (0.40) KDM4EHPGDCA2CA1CA12
SCHEMBL6892823 0.83 FOLH1 (0.39) KDM4EHPGDFOLH1
SCHEMBL6509677 0.81 KDM4E (0.46) KDM4EHPGDCA2CA1CA12
SCHEMBL6511464 0.81 CA2 (0.49) KDM4EHPGDCA2CA1FOLH1
SCHEMBL6508609 0.79 CA2 (0.47) KDM4EHPGDCA2CA1CA12
SCHEMBL6512041 0.79 CA2 (0.47) KDM4EHPGDCA2CA1CA12
SCHEMBL21586412 0.76 KDM4E (0.58) KDM4EHPGDCA2CA1CA12
SCHEMBL18263949 0.76 KDM4E (0.58) KDM4EHPGDCA2CA1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852755-B1 Nitrogen mustard compounds and prodrugs therefor CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2005-02-08 US claimed
EP-1165493-B1 NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR CANCER REC TECH LTD (GB) 2005-01-19 EP claimed
EP-1165493-A1 NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2002-01-02 EP claimed
WO-2000058271-A1 NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2000-10-05 WO claimed
US-20250339482-A1 Recombinant Herpes Simplex Virus for Cancer Immunotherapy THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2025-11-06 US disclosed
EP-3801583-B1 RECOMBINANT HERPES SIMPLEX VIRUS FOR USE IN A TREATMENT OF CANCER UNIV ILLINOIS (US) 2025-07-02 EP disclosed
US-12329794-B2 Recombinant herpes simplex virus for cancer immunotherapy THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2025-06-17 US disclosed
EP-1914316-B1 LIVP strain of vaccinia virus for diagnosis and therapy of tumours GENELUX CORP (US) 2009-12-16 EP disclosed
EP-1414994-B9 VACCINIA VIRUS FOR DIAGNOSIS AND THERAPY OF TUMORS GENELUX CORP (US) 2008-11-12 EP disclosed
EP-1914316-A2 Microorganisms and cells for diagnosis and therapy of tumors Genelux Corporation (US) 2008-04-23 EP disclosed
EP-1414994-B1 VACCINIA VIRUS FOR DIAGNOSIS AND THERAPY OF TUMORS GENELUX CORP (US) 2007-10-10 EP disclosed
US-6852755-B1 Nitrogen mustard compounds and prodrugs therefor CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2005-02-08 US disclosed
EP-1165493-B1 NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR CANCER REC TECH LTD (GB) 2005-01-19 EP disclosed
EP-1165493-A1 NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2002-01-02 EP disclosed
WO-2000058271-A1 NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2000-10-05 WO disclosed